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Abstract
Background—Conventional therapy with β-blockers is incompletely effective in preventing
arrhythmic events in patients with catecholaminergic polymorphic ventricular tachycardia
(CPVT). We have previously discovered that flecainide in addition to conventional drug therapy
prevents ventricular arrhythmias in genotype-positive CPVT patients.
Objective—To study the efficacy of flecainide in genotype-negative CPVT patients.
Methods—We studied the efficacy of flecainide for reducing ventricular arrhythmias during
exercise testing and preventing arrhythmia events during long-term follow-up.
Results—Twelve genotype-negative CPVT patients were treated with flecainide. Conventional
therapy failed to control ventricular arrhythmias in all patients. Flecainide was initiated because of
significant ventricular arrhythmias (n=8), syncope (n=3), or cardiac arrest (n=1). At the baseline
exercise test before flecainide, 6 patients had ventricular tachycardia and 5 patients had bigeminal
or frequent ventricular premature beats. Flecainide reduced ventricular arrhythmias at the exercise
test in 8 patients compared to conventional therapy, similarly to genotype-positive patients in our
previous report. Notably, flecainide completely prevented ventricular arrhythmias in 7 of the
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patients. Flecainide was continued in all patients except for one who had ventricular tachycardia at
the exercise test on flecainide. During a follow-up of 48±94 months, arrhythmia events (sudden
cardiac death and aborted cardiac arrest) associated with noncompliance occurred in two patients.
Flecainide was not discontinued due to side effects in any of the patients.
Conclusion—Flecainide was effective in genotype-negative CPVT patients, suggesting that
spontaneous Ca2+ release from ryanodine channels plays a role in arrhythmia susceptibility,
similarly to genotype-positive patients.
Keywords
catecholaminergic polymorphic ventricular tachycardia; arrhythmia; sudden death; genetics;
antiarrhythmic drugs; flecainide; beta-blockers
Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia
syndrome characterized by bidirectional or polymorphic VT induced by adrenergic stress in
the absence of structural heart disease.1-3 Three causative genes have been identified for
CPVT: RYR2, which encodes the cardiac ryanodine receptor Ca2+ release channel, CASQ2,
which encodes cardiac calsequestrin, and TRDN, which encodes triadin, and all of them are
constitutive proteins of the macromolecular Ca2+ release complex in the sarcoplasmic
reticulum.4-7 A mutation in these genes is identified in approximately 60-70% of patients
with CPVT.2, 8 A locus on chromosome 7p14-p22 has also been linked to CPVT, but a
corresponding gene has not been identified yet.9 Furthermore, mutations in KCNJ2
encoding the potassium inwardly-rectifying channel Kir2.1, which generally are associated
with Andersen-Tawil syndrome, may phenocopy CPVT.10
Treatment with β-adrenergic blockers reduces ventricular arrhythmia burden and mortality
in patients with CPVT. However, the efficacy of β-blockers is not sufficiently protective and
an estimated 8-year rate of fatal or near-fatal events on β-blocker therapy is 15%.2, 3
Although the beneficial effects of the calcium channel blocker verapamil in combination
with a β-blocker have been reported,11-14 the role of verapamil has not been well assessed.2
Left cardiac sympathetic denervation has been reported to be highly effective in severely
affected patients, but requires surgery and is not universally available.15 Implantable
cardioverter defibrillators (ICDs) are recommended for prevention of sudden death in
patients with CPVT.16 However, painful shocks can trigger further adrenergic stress and
arrhythmias, and deaths have occurred despite appropriate ICD shocks.17, 18 We have
recently discovered that the antiarrhythmic agent flecainide inhibits Ca2+ release from
ryanodine receptor19 and that flecainide in addition to conventional drug therapy prevents
ventricular arrhythmias in CPVT patients carrying a mutation in RYR2 or CASQ2.3 Here,
we studied the efficacy and safety of flecainide in CPVT patients with no mutations in
RYR2, CASQ2 and KCNJ2, who have similar risk of arrhythmia events to genotype-
positive patients.2
Methods
Study population
This study included all consecutive genotype-negative CPVT patients in whom flecainide
was started because of the insufficient efficacy of conventional therapy with β-blockers ±
verapamil at 5 tertiary referral centers in the Netherlands, the United Kingdom, Israel, Japan,
and Germany. All patients had a clinical diagnosis of CPVT based on adrenergic stress-
induced bidirectional or polymorphic VT in the absence of structural heart abnormalities by
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echocardiography.20 All families received genetic counseling and all investigated
individuals consented to both cardiologic evaluation and genetic testing. Patients were
screened for a putative pathogenic mutation in all exons of RYR2, CASQ2, and KCNJ2.
Only individuals who were not carrying proven or putative pathogenic mutations in all of
these genes were included. Decisions on administration of flecainide and its dose were made
by the local cardiologists. Data collection and analysis were done retrospectively by chart
review. Patients in whom the dose of β-blocker or verapamil was increased after the
initiation of flecainide were not included in this study.
Outcome measures
The efficacy of flecainide on CPVT was compared between the last exercise test on
conventional therapy and the first exercise test on a stable dose of flecainide after ≥5 days of
the initiation. Exercise testing was performed using treadmill (standard or modified Bruce
protocols) or bicycle ergometer depending on the institutions. Ventricular arrhythmias
during exercise testing were quantified using the ventricular arrhythmia score defined by the
worst ventricular arrhythmia observed: 1=no or isolated ventricular premature beats (VPBs),
2=bigeminal VPBs and/or >10 VPBs per minute, 3=couplet, 4=NSVT.20 In addition, the
presence of either of the parameters of the ventricular arrhythmia score, sinus rate at the
onset of ventricular ectopy, most often an isolated VPB, the maximum number of VPBs
during a 10-seconds period, and the ratio of VPBs/sinus beats during the 10-seconds period
with the maximum number of VPBs were analyzed. The effects of flecainide on arrhythmic
events including syncope, aborted cardiac arrest, appropriate ICD shocks, and sudden
cardiac death during follow-up were also assessed.
Data analysis
Values are expressed as mean±SD. To study the effects of flecainide during exercise testing,
related data were compared using paired Wilcoxon signed-rank test for continuous and
ordinal variables and McNemar test for dichotomous variables. All statistical analyses were
performed with SPSS, version 20.0 (SPSS Inc., Chicago, IL). A two-sided P <0.05 was
considered statistically significant.
Results
Patient characteristics
We identified 12 genotype-negative CPVT patients who received flecainide (Table 1). Mean
age at baseline was 22±11 years and 6 patients were female. Our cohort included 7 patients
with a family history of CPVT (6 probands and 1 family member). Nine patients had a
history of syncope and/or cardiac arrest. In patient #6, a common variant of unknown
significance (VUS), p.Val507Ile, was identified in RYR2. Patient #11 tested heterozygote
positive for two new VUS in CASQ2: c.158G>T (p.Cys53Phe) and c.838+3A>G. The c.
158G>T VUS was once detected in 13000 control alleles, whereas the c.838+3A>G may
affect splicing at the donorsite of exon 8 and was not detected in 13000 control alleles.
Before the initiation of flecainide, β-blockers failed to suppress ventricular arrhythmias in all
patients. In 7 patients, multiple drugs including β-blockers, verapamil, and other
antiarrhythmic drugs failed to suppress ventricular arrhythmias before flecainide was
initiated.
Effects of flecainide on exercise-induced ventricular arrhythmias
Among genotype-negative patients, 6 patients (50%) had VT and 5 patients (42%) had
couplet or bigeminal VPBs at the baseline exercise testing before flecainide administration
(Tables 1 and 2). In a remaining patient who had syncope during a combination therapy with
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propranolol and verapamil (patient #3), there was no ventricular arrhythmia during the
baseline exercise testing. Flecainide improved the ventricular arrhythmia score at exercise
testing in 8 patients (67%) compared to that during conventional therapy (Figure), while the
maximum workload during flecainide therapy was increased compared to that during
conventional drug therapy (Table 2). The effects of flecainide seemed similar to that in
genotype-positive patients in our previously report (76%).20 Flecainide completely
suppressed ventricular arrhythmias in 7 patients (58%) and suppressed VT in 4 of the 6
patients who developed VT during the baseline testing. Compared to the baseline exercise
test, flecainide reduced the maximum number of VPBs during a 10-seconds period. In one
patient (patient #10), flecainide was discontinued because of VT during exercise testing.
Effects of flecainide on arrhythmia events
A total of 11 patients (92%) continued to receive flecainide and were included in the further
analysis of the incidence of arrhythmic events. During a mean follow-up of 48±94 months,
arrhythmia events associated with noncompliance occurred in 2 of 11 genotype-negative
patients. Patients #6 died suddenly while playing soccer. Although flecainide combined with
nadolol suppressed ventricular tachycardias during exercise testing, the patient self-
discontinued the drug therapy after his last visit to the clinic. Patient #1 collapsed and was
resuscitated by his relatives. The patient had not taken flecainide from the night before the
collapse, and the serum level of flecainide was low (0.13 mg/L; therapeutic range, 0.4-0.9
mg/L) at the event. Metoprolol and flecainide were resumed at the previous doses, and no
event occurred thereafter. In the remaining 9 patients, there was no arrhythmia event during
the follow-up period, while 7 of the 9 patients had arrhythmia events despite conventional
drug therapy before the initiation of flecainide. Flecainide was not discontinued due to side
effect in any of the patients.
Discussion
In this study, flecainide suppressed ventricular arrhythmias during exercise testing in
genotype-negative patients similar to genotype-positive CPVT patients. Flecainide was
highly effective in preventing arrhythmia events during a long-term follow-up.
CPVT has been associated with mutations in RYR2, CASQ2, and TRDN.4-7 Mutations in
these genes destabilize the ryanodine channel complex in the sarcoplasmic reticulum and
result in spontaneous Ca2+ release through the ryanodine channel leading to delayed after
depolarizations, triggered activity, and VT.21-24 Recently, we and others have identified the
therapeutic effects of flecainide in CPVT.19, 25, 26 Flecainide directly inhibits the ryanodine
channel and suppresses delayed afterdepolarizations and triggered activity in mutant
cardiomyocytes in which Ryr2 or Casq2 loci are modified.19, 26, 27 In our mouse model of
CPVT, flecainide prevents spontaneous VT and inducible VT by exercise or isoproterenol.19
Yet, we have recently discovered that flecainide prevents CPVT in patients carrying a
mutation in RYR2 or CASQ2, possibly resulting in spontaneous Ca2+ release.19, 20 In this
study, flecainide was also effective in genotype-negative CPVT patients, similarly in
genotype-positive patients in our prior study.20 Notably, all arrhythmia events during
flecainide therapy were associated with noncompliance in our present and prior studies.20
The efficacy of flecainide in genotype-negative CPVT patients suggests that uncontrolled
Ca2+ release through the ryanodine channel is also important as the underlying mechanisms
in patients without an identified mutation in RYR2 or CASQ2, that account for 30-40% of
patients with CPVT.3, 28 There are a certain number of CPVT patients with positive family
history but negative genotyping results, suggesting the presence of other causative genes that
have not been identified yet. Unknown genetic backgrounds of CPVT may include genes
encoding the constitutive proteins and the modifiers of macromolecular Ca2+ release
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complex. For example, homozygosity for mutations in TRDN encoding triadin, an
anchoring protein of calsequestrin to ryanodine channel, has very recently been identified in
families affected by CPVT.7 Furthermore, flecainide may suppress CPVT through sodium
channel blocking effects as we and others have previously proposed.19, 26
Genotype-phenotype correlations have been studied in inherited arrhythmia syndromes. The
genotype contributes to risk stratification and impacts on therapeutic decisions in long QT
syndrome; the most studied arrhythmia syndrome.29 In CPVT, the risk of arrhythmia events
and the efficacy of β-blocker seem to be similar in genotype-positive and genotype-negative
patients.2 Our findings indicate that flecainide can be used regardless of genotyping results
in CPVT patients in whom β-blockers fail to control their ventricular arrhythmias or
symptoms.
Our study has several limitations. The number of patients was limited because CPVT is a
very rare disease. Therefore, the efficacy of flecainide could not be systematically assessed
and further studies, probably randomized controlled studies, are needed.30 Patients with
CPVT whose arrhythmias are refractory to the conventional drug therapy were included in
this study and our previous study.20 Therefore, the efficacy of flecainide in patients whose
arrhythmias are well responded to the conventional therapy is not known. Exercise testing is
used to assess the effects of therapies in CPVT and our previous study showed that
ventricular arrhythmia scores at exercise testing are reproducible measures of drug efficacy
in CPVT20 However, the predictive ability of ventricular arrhythmia scores for arrhythmia
events is not clear. Finally, the patients in this study were not tested for mutations in
TRDN.7 However, in this study, none of the patients were from a consanguineous family, so
the possibility of identifying mutations in TRDN seems very low.
In conclusion, we found that flecainide was effective in suppressing ventricular arrhythmias
during exercise and preventing arrhythmia events in genotype-negative CPVT patients,
similarly to genotype-positive patients. Our results suggest that flecainide can be added,
regardless of genotype, to control ventricular arrhythmias or symptoms, when they are
insufficiently controlled by conventional therapy with β-blockers.
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Figure.
Effects of flecainide on exercise-induced ventricular arrhythmias. Ventricular arrhythmias
during exercise testing were compared between conventional therapy and flecainide in
genotype-negative patients. Green line indicates suppression of ventricular arrhythmias by
flecainide; blue line, no change. VT denotes ventricular tachycardia; VPB, ventricular
premature beat.
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Table 2
Effects of flecainide on ventricular arrhythmias during exercise testing
Standard therapy Flecainide P-value
Sinus rate at baseline, beats/min 68±14 72±28 0.82
Sinus rate at maximal exercise, beats/min 148±26 136±23 0.33
Maximum workload attained, METs 9±3 11±3 0.19
Sinus rate at onset of ventricular arrhythmias, beats/min 114±34 117±23 0.50
Maximum no. of VPBs during a 10 seconds 12±7 6±7 0.02
Ratio of VPBs to sinus beats during 10 seconds with the maximum no. of VPBs 1.5±2.6 0.5±0.6 0.21
Isolated VPB 11 (92) 6 (50) 0.03
Bigeminal VPBs 10 (83) 5 (42) 0.03
Frequent VPBs (>10/min) 9 (75) 5 (42) 0.10
Couplet 8 (67) 3 (25) 0.10
Nonsustained ventricular tachycardia 6 (50) 2 (17) 0.10
Longest ventricular salvo, VPBs 9.5 (3-16) 5 (4-6) 0.13
Bidirectional NSVT 4 (33) 1 (8) 0.08
Values are mean±SD or number (%).
Heart Rhythm. Author manuscript; available in PMC 2013 October 28.
